Log in

TSE:THTheratechnologies Stock Price, Forecast & News

C$2.36
+0.05 (+2.16 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
C$2.32
Now: C$2.36
C$2.42
50-Day Range
C$2.31
MA: C$2.99
C$4.03
52-Week Range
C$1.93
Now: C$2.36
C$7.98
Volume125,009 shs
Average Volume136,080 shs
Market CapitalizationC$181.64 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States. The company was founded in 1993 and is headquartered in Montreal, Canada.
Read More
Theratechnologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.11 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-514-3367800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$63.84 million
Cash FlowC$0.46 per share
Book ValueC$0.27 per share

Profitability

Miscellaneous

Employees32
Market CapC$181.64 million
Next Earnings Date7/9/2020 (Estimated)
OptionableNot Optionable

Receive TH News and Ratings via Email

Sign-up to receive the latest news and ratings for TH and its competitors with MarketBeat's FREE daily newsletter.

Theratechnologies (TSE:TH) Frequently Asked Questions

How has Theratechnologies' stock been impacted by COVID-19 (Coronavirus)?

Theratechnologies' stock was trading at C$3.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TH stock has decreased by 21.3% and is now trading at C$2.36. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Theratechnologies?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Theratechnologies.

When is Theratechnologies' next earnings date?

Theratechnologies is scheduled to release its next quarterly earnings announcement on Thursday, July 9th 2020. View our earnings forecast for Theratechnologies.

How were Theratechnologies' earnings last quarter?

Theratechnologies Inc (TSE:TH) released its quarterly earnings data on Tuesday, April, 14th. The company reported ($0.08) earnings per share for the quarter. The business had revenue of $20.71 million for the quarter, compared to the consensus estimate of $24.53 million. View Theratechnologies' earnings history.

What price target have analysts set for TH?

4 analysts have issued twelve-month target prices for Theratechnologies' stock. Their forecasts range from C$4.00 to C$7.00. On average, they anticipate Theratechnologies' share price to reach C$5.67 in the next twelve months. This suggests a possible upside of 140.1% from the stock's current price. View analysts' price targets for Theratechnologies.

Has Theratechnologies been receiving favorable news coverage?

Press coverage about TH stock has been trending negative on Saturday, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Theratechnologies earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutTheratechnologies.

Who are some of Theratechnologies' key competitors?

What other stocks do shareholders of Theratechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Stars Group (TSGI), BCE (BCE), ProMetic Life Sciences (PLI), Theratechnologies (THERF), Teranga Gold (TGZ), Endeavour Mining (EDV), Nemaska Lithium (NMX), Shopify (SHOP), United Therapeutics (UTHR) and Avigilon (AVO).

Who are Theratechnologies' key executives?

Theratechnologies' management team includes the following people:
  • Mr. Luc Tanguay, Pres, CEO & Non-Independent Director (Age 61)
  • Mr. Philippe Dubuc MBA, Sr. VP & CFO (Age 52)
  • Mr. Jocelyn Lafond, VP of Legal Affairs & Corp. Sec. (Age 51)
  • Mr. Denis Boucher B.A., L.L.B., VP of Communications & Corp. Affairs (Age 53)
  • Mr. Christian Marsolais, Sr. VP & Chief Medical Officer (Age 56)

What is Theratechnologies' stock symbol?

Theratechnologies trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TH."

How do I buy shares of Theratechnologies?

Shares of TH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Theratechnologies' stock price today?

One share of TH stock can currently be purchased for approximately C$2.36.

How big of a company is Theratechnologies?

Theratechnologies has a market capitalization of C$181.64 million and generates C$63.84 million in revenue each year. Theratechnologies employs 32 workers across the globe.

What is Theratechnologies' official website?

The official website for Theratechnologies is www.theratech.com.

How can I contact Theratechnologies?

Theratechnologies' mailing address is 2015 Peel St 5th Floor, MONTREAL, QC H3A 1T8, Canada. The company can be reached via phone at +1-514-3367800.

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.